NCT01415011 - Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

August 31, 2015

Study Completion Date

November 30, 2018

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Afatinib (BIBW 2992)

All patients will be given daily oral afatinib (BIBW 2992) administered every 28 days until disease progression/toxicity/clinician decision to stop. Starting dose is 40mg. 30mg and 20mg will be administered according to protocol dose modification requirements following toxicity.

Trial Locations (15)

Unknown

Royal Bournemouth Hospital, Bournemouth

Beatson West of Scotland Cancer Centre, Glasgow

James Paget University Hospital, Great Yarmouth

East Kent Hospitals, Kent

Maidstone Hospital, Kent

St James's University Hospital, Leeds

Barnet & Chase Farm Hospitals, London

Charing Cross Hospital, London

Guy's Hospital, London

University College Hospital, London

Musgrove Park Hospital, Somerset

The Royal Marsden Hospitals, Sutton

King's Mill Hospital, Sutton in Ashfield

Weston General Hospital, Weston-super-Mare

York Hospital, York